Biofil Chemicals & Pharmaceuticals share news, announcements and annual reports
NSE: BIOFILCHEMBSE: 524396Pharmaceuticals & BiotechnologySmall Cap
Biofil Chemicals & Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1994 on BSE, Jun 1996 on NSE
Last close ₹28.68down ₹0.73 (2.48%)BSE ₹29.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹29.41.
30 Oct: open ₹29.00, high ₹29.80, low ₹28.26
52-week range of traded prices to 30 Oct 2026
₹25.60Low, 30 Mar 2026₹46.34High, 3 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹47 Cr3,363rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 96.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.16
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 2.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.14
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,71974.4% delivered
Biofil Chemicals & Pharmaceuticals shareholding disclosures
19 filed, newest first.
May 2026
Jun 2025
May 2024
Jun 2023
Apr 2022
Apr 2021
May 2020
Apr 2019
Apr 2018
Apr 2017
Apr 2016
Apr 2015
Apr 2011
Feb 2009
24 Feb · Disclosure
Biofil Chemicals & Pharmaceuticals Ltd. has informed the Exchange that promoters of the company have confirmed that none of their shareholding in the company are pledged as on 28.01.2009. Further the company has submitted to the Exchange a copy of disclosure pursuant to regulation 8A of SEBI (SAST) Amendments Regulations, 2009. A copy of the shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
30 Jul · Disclosure
Ramesh Shah alongwith Smitesh Shah, Ketan Shah and Sandeep Shah proposes to acquire 1284200 equity shares aggregating to 12.16% of the shares/voting rights of Biofil Chemicals & Pharmaceuticals Limited from Systematix Corporate Services Limited, Systematix Leasing & Investments Ltd. (Now Gems Equities & Securities Pvt Ltd). and Systematix Mercantile Ltd. The mode of proposed acquisition is by way of Inter-se Promoter Transfer & the date of proposed acquisition is August 05, 2008. The proposed acquisition price per share is Proposed to be an off market transaction (Rs. 0.36 per share). The shareholding of Ramesh Shah, Smitesh Shah, Ketan Shah and Sandeep Shah after the proposed acquisition would be 1599300 shares aggregating to 15.14% of the shares/voting rights of Biofil Chemicals & Pharmaceuticals Limited. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.